More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome — but approval isn’t a su…
Paris-based pharma Sanofi-Aventis has pushed back its offer deadline for Massachusetts-based biotech Genzyme by six weeks. All other terms, including the $69 per share bid, remain unchanged. So far, very few shareholders have r…
By the time the world’s smartest investors tell the SEC what stocks they hold, most of the gains they were after are already priced in. But a few of the companies Warren Buffett, George Soros, and their billionaire buddies have…
Big Pharma didn’t rest Thursday, with Celgene, Sanofi-Aventis and AstraZeneca among the big names reporting earnings. A deal between Stryker and Boston Scientific and Sanofi and BMP Sunstone also made the headlines, as did some…
Genzyme, which makes drugs to treat leukemia and multiple sclerosis, has rejected a hostile takeover bid from French drugmaker Sanofi-Aventis. The offer “dramatically undervalues” Genzyme, the company said Friday, putting its v…